GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inoviq Ltd (ASX:IIQ) » Definitions » Institutional Ownership

Inoviq (ASX:IIQ) Institutional Ownership : 0.05% (As of Jun. 05, 2024)


View and export this data going back to 1991. Start your Free Trial

What is Inoviq Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Inoviq's institutional ownership is 0.05%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Inoviq's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Inoviq's Float Percentage Of Total Shares Outstanding is 0.00%.


Inoviq Institutional Ownership Historical Data

The historical data trend for Inoviq's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inoviq Institutional Ownership Chart

Inoviq Historical Data

The historical data trend for Inoviq can be seen below:

2023-06-30 2023-07-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 0.05 0.08 0.11 0.11 0.11 0.11 0.11 0.05 0.05 0.05

Inoviq Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Inoviq (ASX:IIQ) Business Description

Traded in Other Exchanges
N/A
Address
23 Normanby Road, Notting Hill, Melbourne, VIC, AUS, 3168
Inoviq Ltd is engaged in developing and commercializing a portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The company has commercialized the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

Inoviq (ASX:IIQ) Headlines

No Headlines